We found that the mTOR inhibitor rapamycin inhibited the transcriptional activation of the FASN promoter and FASN mRNA expression in breast cancer cells, especially in ER+/HER2+ breast cancer cells. This evidence concerns the gene ERBB2 and breast carcinoma.